| Literature DB >> 34066921 |
Christoph Portier1, Chris Vervaet1, Valérie Vanhoorne1.
Abstract
Continuous twin screw wet granulation is one of the key continuous manufacturing technologies that have gained significant interest in the pharmaceutical industry as well as in academia over the last ten years. Given its considerable advantages compared to wet granulation techniques operated in batch mode such as high shear granulation and fluid bed granulation, several equipment manufacturers have designed their own manufacturing setup. This has led to a steep increase in the research output in this field. However, most studies still focused on a single (often placebo) formulation, hence making it difficult to assess the general validity of the obtained results. Therefore, current review provides an overview of recent progress in the field of continuous twin screw wet granulation, with special focus on the importance of the formulation aspect and raw material properties. It gives practical guidance for novel and more experienced users of this technique and highlights some of the unmet needs that require further research.Entities:
Keywords: continuous manufacturing; formulation development; innovation; process development; review; twin screw granulation; wet granulation
Year: 2021 PMID: 34066921 PMCID: PMC8148523 DOI: 10.3390/pharmaceutics13050668
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Advantages of continuous manufacturing.
Figure 2Setup of two fully integrated powder-to-tablet lines. (Top): Consigma by GEA Pharma Systems (adopted from www.gea.com; accessed on 9 April 2021); (bottom): QbCon by L.B. Bohle (courtesy of L.B. Bohle).
Figure 3Evolution in publications on continuous pharmaceutical manufacturing and pharmaceutical twin screw granulation, indexed in PubMed as Continuous-Manufacturing AND Pharmaceutical (blue) and Pharmaceutical AND Twin-Screw AND Granulation (orange), respectively.
Overview of research papers on twin screw wet granulation evaluating formulations consisting of an API and a filler combination of MCC and lactose.
| Water Soluble Filler (Grade) | Ratio Water Soluble Filler/MCC | API | Granular API | Reference(s) |
|---|---|---|---|---|
| Lactose (Pharmatose 200M) | 1 | Acetaminophen | 5% | [ |
| Lactose (Flowlac 100) | 1 | Acetaminophen | 15% | [ |
| Lactose (Pharmatose 200M) | 2.33 | Albendazole | 50% | [ |
| Lactose (Flowlac 100) | 1 | Caffeine | 15% | [ |
| Lactose (Flowlac 100) | 1 | Griseofulvin | 15% | [ |
| Lactose (Pharmatose 200M) | 1 | Hydrochlorothiazide | 60% | [ |
| Lactose (Flowlac 100) | 1 | Ibuprofen | 15% | [ |
| Lactose (Granulac 70) | 1.33 | Ibuprofen | 30% | [ |
| Lactose (Granulac 200) | 1.4 | Ibuprofen | 51.5% | [ |
| Lactose (Pharmatose 200M) | 1 | Mebendazole | 5% | [ |
| Lactose (Pharmatose 200M) | 1 | Mebendazole | 10% | [ |
| Lactose (Pharmatose 200M) | 1 | Mebendazole | 50% | [ |
| Lactose (Pharmatose 200M) | 1 | Metformin.HCl | 5% | [ |
| Lactose (Pharmatose 200M) | 1 | Metformin.HCl | 10% | [ |
| Lactose (Pharmatose 200M) | 1 | Metformin.HCl | 50% | [ |
| Lactose (Pharmatose 200M) | 1 | Theophylline | 5% | [ |
Overview of research papers on twin screw wet granulation evaluating formulations consisting of an API and a filler combination of MCC and mannitol.
| Water Soluble Filler (Grade) | Ratio Water Soluble Filler/MCC | API | Granular API | Reference(s) |
|---|---|---|---|---|
| Mannitol (Pearlitol 160C) | 1 | Acetaminophen | 25% | [ |
| Mannitol (Pearlitol 160C) | 1 | Allopurinol | 25% | [ |
| Mannitol (Pearlitol 200SD) | 1 | Allopurinol | 25% | [ |
| Mannitol (Pearlitol 160C) | 1 | Metformin.HCl | 25% | [ |
| Mannitol (Pearlitol 160C) | 2.08 | Not disclosed | 22% | [ |
Figure 4Friability contour plots of formulations containing 5% HPMC, lactose/MCC (1:1) as filler and (A) 5% acetaminophen, (B) placebo, (C) 5% theophylline anhydrous, (D) 10% mebendazole, and (E) 10% metformin hydrochloride. Adapted with permission from [12], Elsevier, 2020.